These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15538119)

  • 1. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center.
    Wonodi I; Adami HM; Cassady SL; Sherr JD; Avila MT; Thaker GK
    J Clin Psychopharmacol; 2004 Dec; 24(6):592-8. PubMed ID: 15538119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
    Glazer WM; Morgenstern H; Doucette JT
    J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa.
    Patterson BD; Swingler D; Willows S
    Schizophr Res; 2005 Jul; 76(1):89-97. PubMed ID: 15927802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Maryland Psychiatric Research Center scale and the characterization of involuntary movements.
    Cassady SL; Thaker GK; Summerfelt A; Tamminga CA
    Psychiatry Res; 1997 Apr; 70(1):21-37. PubMed ID: 9172274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cross-Sectional Study on the Characteristics of Tardive Dyskinesia in Patients with Chronic Schizophrenia.
    Huang Y; Pan L; Teng F; Wang G; Li C; Jin L
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):295-303. PubMed ID: 29276353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
    Chakos MH; Alvir JM; Woerner MG; Koreen A; Geisler S; Mayerhoff D; Sobel S; Kane JM; Borenstein M; Lieberman JA
    Arch Gen Psychiatry; 1996 Apr; 53(4):313-9. PubMed ID: 8634009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
    Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
    Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tardive dyskinesia among Chinese and Malay patients with schizophrenia.
    Chong SA; Mahendran R; Machin D; Chua HC; Parker G; Kane J
    J Clin Psychopharmacol; 2002 Feb; 22(1):26-30. PubMed ID: 11799339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Awareness of tardive dyskinesia in Asian patients with schizophrenia.
    Chong SA; Remington G; Mahendran R; Chua HC
    J Clin Psychopharmacol; 2001 Apr; 21(2):235-7. PubMed ID: 11270922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia: who is at risk?
    van Os J; Fahy T; Jones P; Harvey I; Toone B; Murray R
    Acta Psychiatr Scand; 1997 Sep; 96(3):206-16. PubMed ID: 9296552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.